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Abstract
Similar retinitis pigmentosa (RP) phenotypes can result from mutations aVecting diVerent rhodopsin regions, and distinct amino acid substi-
tutions can cause diVerent RP severity and progression rates. SpeciWcally, both the R135L and R135W mutations (cytoplasmic end of H3)
result in diVuse, severe disease (class A), but R135W causes more severe and more rapidly progressive RP than R135L. The P180A and G188R
mutations (second intradiscal loop) exhibit a mild phenotype with regional variability (class B1) and diVuse disease of moderate severity (class
B2), respectively. Computational and in vitro studies of these mutants provide molecular insights into this phenotypic variability.
© 2006 Elsevier Ltd. All rights reserved.
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RHO mutations aVecting the amino acidic sequence of
the rod-speciWc protein rhodopsin are responsible primarily
for autosomal dominant retinitis pigmentosa (ADRP) and
account for 30–40% of this form of RP (source: RetNet:
http://www.sph.uth.tmc.edu/Retnet/ disease.htm#03.202d)
(RetNet—Retinal Information Network). Uncertainty
remains regarding the disease severity, rate of progression,
and clinical–functional phenotypes associated with speciWc
RHO mutations. Accordingly, the determinants of disease
expression and severity remain incompletely characterized.
Many RHO mutations have been studied in vitro, and
valuable classiWcation schemes of the in vitro behavior of
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doi:10.1016/j.visres.2006.08.018the mutants studied have been proposed (Kaushal & Khor-
ana, 1994; Sung, Davenport, & Nathans, 1993; Sung,
Schneider, Agarwal, Papermaster, & Nathans, 1991). How-
ever, not all clinically relevant mutations have yet been
studied, and these classiWcation schemes do not always
correlate well with clinical disease expression or severity.
SigniWcant progress in understanding the disease sequence
and phenotypic characteristics were made when a classiWca-
tion of rhodopsin phenotypes based on the combination of
various clinical and functional criteria was developed
(Cideciyan et al., 1998). However, to date, neither has this
proposed classiWcation system been corroborated by inde-
pendent investigations, nor has it yet been routinely applied
to families harboring other mutations.
The Wrst objective of this report is to illustrate the clini-
cal and functional manifestations and the variability in
severity and disease progression rates of RP associated with
diVerent rhodopsin changes aVecting distinct portions of
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(Fig. 1): two distinct mutations aVecting codon 135, the
arginine to tryptophan (Arg-135-Trp, or R135W) and the
argine to lysine (Arg-135-Lys, or R135L) changes, aVecting
an amino acid at the cytoplasmic edge of the third rhodop-
sin transmembrane helix (H3); and two changes in the sec-
ond intradiscal loop (E2), the proline to alanine change at
codon 180 (Pro-180-Ala, or P180A) and the glycine to
arginine change at codon 188 (Gly-188-Arg, or G188R).
Fig. 1. Secondary structure model of rhodopsin illustrating the location of
the four mutations investigated in this manuscript: R135L and R135W,
aVecting the cytoplasmic edge of H3; and P180A and G188R, involving
the second intradiscal loop (E2). In red and blue are highlighted the two
largest clusters of mutually rigid residues belonging to the core of stability
identiWed by FIRST analysis.All sequence changes have been previously associated with
ADRP, but P180A has been reported only in a seemingly
isolated case of RP (Sohocki et al., 2001). Our Wndings dem-
onstrate that similar clinical–functional phenotypes can
result from mutations aVecting diVerent regions of rhodop-
sin, and that distinct amino acid changes at the same codon
can result in identical overall phenotypic classes but diVer-
ent RP severity and progression rates.
Second, to test the hypothesis that these clinical Wndings
could be explained at least in part by structural and func-
tional diVerences between these mutants, and to conWrm
the pathogenicity of the P180A change, computational
analyses and in vitro experiments have been performed. We
show that the P180A change has characteristics consistent
with pathogenicity, and that misfolding and stability pre-
dictions and the corresponding characteristics experimen-
tally observed in puriWed mutant proteins as well as their
glycosylation and aggregation patterns correlate well with
the gradient of severity observed among these four
mutants, providing insight into the observed phenotypic
variability.
2. Materials and methods
Data from four families (Fig. 2) are included in this report. Onset and
type of symptoms, best corrected visual acuity to either Snellen or ETDRS
charts, clinical presentation, Goldmann visual Welds, and Xash ERGs were
analyzed in 16 subjects (age: 3–64). To characterize disease expression in
our families, we utilized the criteria set forth by Cideciyan et al. (1998). All
procedures were conducted in accordance with the declaration of Helsinki.
Blood samples were collected after obtaining signed informed consent
from all subjects participating in the molecular genetic research studies,
which were approved by the Institutional Review Boards of all participat-
ing institutions.Fig. 2. Pedigrees of the four families investigated in this study. Arrows identify the probands from each family. The horizontal bar above the symbols cor-
respond to examined subjects. Filled symbols identify aVected individuals. In the P180A pedigree, the half-Wlled symbol (III:1) identiWes a subject who
reportedly suVered from glaucoma, and the “+” symbols indicate obesity (BMI>30).
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Goldmann visual Welds to I4e and V4e targets were performed and
their areas were measured in all patients using previously reported tech-
niques (Iannaccone et al., 1995, 2004; Iannaccone, 2003). ERGs were
recorded at diVerent laboratories with monopolar electrodes according to
standard procedures in compliance with the ISCEV standards (Marmor,
Holder, Seeliger, & Yamamoto, 2004). The ERGs performed on the two
Italian families were recorded according to methods also reported previ-
ously in detail (Del Porto et al., 1993; Iannaccone et al., 1995; Koenekoop
et al., 2002; Pannarale et al., 1996; Rispoli, Iannaccone, & Vingolo, 1994).
To allow for comparison of data collected with diVerent instruments and/
or electrodes at distinct laboratories, amplitudes have been normalized as
percent of the lowest limit of normal for each setting. When available, also
light-(LA) and dark-adapted (DA) monochromatic automated perimetry
(MAP) data were included in the analyses. The latter data were gathered
according to the technique developed by Jacobson co-workers (Apáthy,
Jacobson, Nghiem-Phu, Knighton, & Parel, 1987; Jacobson & Apáthy,
1988; Jacobson et al., 1986). Further methodological details are provided
in Appendix A. Normative ranges for the ERG responses recorded at
UTHSC are also provided in Supplementary Table 1.
2.2. Patient population
In the Caucasian American family in which a R135L RHO mutation
was identiWed (Fig. 2), we examined a 36-year-old Caucasian male (V:3)
and his symptomatic daughter (VI:2, the proband), who could be evalu-
ated at 3, 6, and 10 years of age. In this family, there was an overt history
of RP, although with no known male-to-male transmission.
The Italian family in which the R135W RHO mutation co-segregated
with RP demonstrated 24 aVected individuals (Fig. 2). Of them, 7 subjects
were available for investigation (subjects IV:5, IV:9, V:7, V:8, V:10, the pro-
band, V:13, and V:14), ranging in age from 6 to 41 years. Information of this
family has been presented in part previously (Pannarale et al., 1996).
In the African–American family harboring the P180A RHO change,
two individuals were investigated (Fig. 2), a 22-year-old male (IV:4, the
proband) and his 47-year-old mother (III:2). Neither subject was aware of
being aVected at the time of examination, the state of aVection having been
discovered in subject IV:4 in the course of a routine eye exam following a
trauma to the head region. There was, however, history of RP in this
family in subjects I:2 and II:2.
Lastly, 14 aVected individuals were identiWed from the Italian family in
which the G188R RHO mutation was found (Fig. 2), 13 of whom by his-
tory. Of these, Wve were available for evaluation (III:11, IV:6, IV:10, IV:16,
and IV:19, the proband). A sixth examined subject, an 8-year-old female
(V:2), was asymptomatic but found to be aVected upon ERG testing.
Investigated subjects from this pedigree ranged in age from 8 to 64 years.
A report on the fundus features of this family has been previously
published (Del Porto et al., 1993).
2.3. Molecular genetic methods
PCR ampliWcation and sequencing of the RHO gene was performed on
genomic DNA extracted from whole blood samples according to manu-
facturer’s speciWcations with DNA QiAmp Blood Maxi kits (Qiagen,
Valencia, CA) or, for the R135W and G188R families, as previously
reported (Del Porto et al., 1993; Pannarale et al., 1996). The primers used
for the ampliWcation of all the Wve exons of rhodopsin have been reported
before (Inglehearn et al., 1991). The PCR ampliWcation was carried in
25 ml reaction volume using Extensor Hi-Fidelity PCR Master Mix
(ABgene, Surrey, UK) according to manufacturer’s instructions. The cycle
conditions were 94 °C for 5 min, followed by 30 cycles of 94 °C for 30 s,
60C° for 30 s and 72 °C for 30 s. The PCR products were treated with Exo-
SAP-IT (Usb Corporation) and sequenced with Big Dye v1.1 according to
manufacturer’s instructions. The sequencing reaction was run on ABI
Prism 3100 DNA Sequencer and the sequences were analysed with
Sequencher v 4.1.4 (Gene Codes).2.4. Computational modeling
2.4.1. Mutational data
We have recently compiled two types of experimental results for stabil-
ity changes upon single-point mutations for mammalian rhodopsin (Isin,
Rader, Dhiman, Klein-Seetharaman, & Bahar, 2006; Rader et al., 2004;
Tastan et al., submitted). First, the percentages of folding as deWned by the
ability to bind 11-cis retinal by the mutant opsins were collected. Retinal
binding was estimated from the ratio between absorbances at 280 and
500 nm. If the mutant showed at least 70% or more of the wild type (WT)
reference, it was considered correctly folded. Second, the eVects on Meta-
rhodopsin II stability as assayed by the half-life of the Xuorescence decay
of light-activated rhodopsin of protein were compiled. This was done
based on the assumption that factors contributing to stability of the
ground state should also do so for the light-activated state. If a decrease in
rate by 25% or more was observed, the mutant was considered to be more
stable. If an increase in rate by 25% or more was observed, the mutant was
considered to be less stable. In the case of mammalian rhodopsin, this
resulted in information on 147 single-point mutations for percent folding
and 159 mutations for Metarhodopsin II stability. Thus, for a total of 279
there is information related to folding and stability jointly.
2.4.2. Stability predictions and simulated thermal unfolding
Mammalian rhodopsin (PDB ID code: 1u19) (Okada et al., 2004)
was used as input for stability predictions by three publicly available
algorithms: I-Mutant2.0 (Capriotti, Fariselli, & Casadio, 2005), DMU-
TANT (Zhou & Zhou, 2002), and FOLDX (Guerois, Nielsen, & Ser-
rano, 2002). In predictions, no distinction was made between increase
and no change in stability as compared to WT. In addition, we used the
FIRST software (Jacobs, Rader, Kuhn, & Thorpe, 2001) to make pre-
dictions of the rhodopsin folding core as previously described (Rader
et al., 2004).
2.5. In vitro experimental methodology
2.5.1. Construction of rhodopsin mutant genes
Single amino acid replacement mutants R135L, R135W, P180A, and
G188R were prepared by a two-step PCR mutagenesis technique as
described in the Supplementary Methods section. The primers used are
also shown in Supplementary Table 2.
2.5.2. Cell culture and transient transfection
Transient transfection of COS-1 cells was as described (Oprian, Mol-
day, Kaufman, & Khorana, 1987) with the exception that cells were har-
vested after 72 h. Proteins were puriWed by 1D4 immunoaYnity
chromatography in 0.05% DM as described (Hwa, Reeves, Klein-Seethar-
aman, Davidson, & Khorana, 1999). The proteins were eluted in PBS
containing 70 M C-terminal nonapeptide and 0.05% (w/v) DM.
2.5.3. UV/Vis absorption spectroscopy
UV/Vis absorption spectra were recorded using a Perkin–Elmer
Lambda 25 UV/Vis spectrophotometer with a bandwidth of 2 nm, a
response time of 1 s, and a scan speed of 240 nm/min at 20 °C. The molar
extinction value (500) used was 40,600 M
¡1 cm¡1.
2.5.4. Deglycosylation with PNGase F
For cleavage of oligosaccharide chains from rhodopsin glycosyla-
tion sites, proteins were deglycosylated with 0.5 U/g of rhodopsin of
PNGase F (New England Biolabs). The puriWed proteins were Wrst
incubated for 1 h at room temperature in denaturing buVer (0.5 M
sodium phosphate, pH 7.5, 0.5% SDS, 40 mM DTT). PNGase F and 1%
NP-40 were then added and the reaction mixture was further incubated
for 6 h.
2.5.5. Polyacrylamide gel electrophoresis and immunoblotting
Protein samples were resolved by SDS–PAGE on 15% polyacryl-
amide–Tris vertical slab gels and transferred onto nitrocellulose
membrane (Bio-Rad) according to standard protocols.
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The clinical and functional features of the 16 subjects
included in this investigation are illustrated in detail in Sup-
plementary Table 3, and the overall phenotypic features
associated with the four RHO mutations herein reported
are summarized in Supplementary Table 4. The following
sections summarize the most salient Wndings for each
mutation.
3.1. R135W and R135L: Two class A mutants resulting in 
diVerent disease severity and progression rates
The R135L and R135W mutations resulted in early-
onset (symptomatic and clinically visible within the Wrst
decade of life, Fig. 3A and B), diVuse, and severe disease,
and rod function was undetectable by ERG criteria since
early childhood (class A) (Cideciyan et al., 1998). Visual
Weld loss of peripheral sensitivity and absolute constriction
were already advanced by the teenage years (Fig. 4A and
B), and ERGs were severely attenuated (always <10%) atall ages (Fig. 4C and D). These Wndings demonstrate that
the retinas of these patients do not ever develop a normal
complement of rods and rod outer segments, and suggest
that cone degeneration is already ongoing at birth. Our
R135W patients also experienced a more severe reduction
in visual acuity then those with the R135L mutation.
Fig. 4E shows that the overall kinetics of ERG b-wave
amplitude loss deduced from cross-sectional data appear
similar between our two families, being both Wt well by log-
arithmic functions. However, unlike R135W patients,
recordable ERGs were retained by our R135L patient
through the late 30s, and their ERGs were signiWcantly
larger at comparable ages. A substantially slower rate of
ERG deterioration from baseline was seen in the R135L
child tested serially (a progressive decline to 75% of base-
line over a 7-year period, equivalent to, on average, a 3.5%
yearly rate) compared to older children with the R135W
mutation, in whom at a 50% year-to-year deterioration rate
was documented. These longitudinal Wndings suggest also
potential for faster disease progression for the R135W-
associated phenotype, at least in teenage years, and for anFig. 3. The composites in (A and B) The ophthalmoscopic Wndings for the right and left eye, respectively, of subject VI:2 from the R135L pedigree at age 6,
an example of a class A phenotype. Although bone spicule-like deposits at this young age are very sparse, they are already visible in both the nasal and
temporal periphery. A moth-eaten appearance of the retinal tissue and dropout of the retinal pigment epithelium are the most prominent features and
aVect both the mid-periphery in all four quadrants and the arcades. The retinal vasculature is already clearly attenuated, and waxy disc pallor is already
visible, despite the high hyperopic refractive defect of this child (+8.00 sph in both eyes). At later age (not shown) prominent bone spicule-like deposits
become apparent and abundant in all four quadrants, and atrophic macular changes appear in these mutants, more notably in association to the R135W
mutation. This presentation contrasts strikingly with that of class B1 phenotypes, exempliWed by the proband harboring the P180A mutation (right and
left eye in (C and D), respectively). The superior retina is essentially normal in appearance and so is the retinal vasculature. A sharply demarcated area of
degeneration is apparent in the inferior retina, characterized by bone spicule-like deposits and whitish Xecks. In this region, mild vascular attenuation can
be noted. The macular area appears free of degenerative changes.
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sible that the non-linearity of the disease progression kinet-
ics accounted for unequal rates in ERG decline at diVerent
ages. Further phenotypic details are provided in Supple-
mentary Table 3.
3.2. P180A and G188R: Similarities and heterogeneity 
within class B mutants aVecting the second intradiscal loop
3.2.1. P180A
Unlike the Class A phenotypes, the asymptomatic pro-
band (subject IV:4) exhibiting a C3820G RHO change,
predicting the P180A amino acid substitution, had clear-
cut altitudinal disease at age 21 (Fig. 3C and D). This was
accompanied by minimal superior Goldmann visual Weld
loss (Fig. 5A), essentially normal cone-mediated and only
mildly abnormal rod-mediated function in the inferior
hemiWeld (Fig. 5B), and fair preservation of rod-driven,
mixed, and cone-driven ERGs (black traces in Fig. 5C).
Sixteen months later, some deterioration of the ERG
responses (blue traces) was observed. SpeciWcally, the
mixed b-wave was 8% smaller from baseline (Fig. 5C and
D). In addition, progression of the disease could be
inferred by the simultaneous reduction in amplitude and
increased delay of the 30-Hz Xicker ERG, an increased
delay in both rod- and cone-driven ERG, as well as other
distinctive changes in DA responses to ¡0.31 cd s/m2
stimuli discussed below.The mother of the proband was also unaware of being
aVected. Although she was not available for fundus photog-
raphy or functional testing, she had clinical features of mild
yet diVuse disease without regional predilection, which was
most compatible with a class B2 phenotype (Cideciyan
et al., 1998). Of likely relevance to this intrafamilial pheno-
typic heterogeneity, and possibly to the sharply altitudinal
disease observed in the proband, the latter had a history of
unusually high exposure to sunlight for occupational
reasons (farm worker). Additional phenotypic details are
presented in Supplementary Table 3.
3.2.2. G188R
Similar to patients with mutations aVecting codon 135,
also the G188R mutation was associated with a diVuse
retinopathy (Del Porto et al., 1993) (see also Supplemen-
tary Table 3). However, the G188R mutation yielded a
much milder phenotype, with symptoms of night blind-
ness as late as age 30. Accordingly, visual Weld constric-
tion associated with this genotype was variable.
Compared to the R135W mutation, twice as large visual
Welds could still be measured in patients at the age of 42
(Fig. 6A). In the Wrst decade of life, no fundus changes
were seen (Del Porto et al., 1993), patients were asymtom-
atic, and mixed ERG amplitude was still 50–60% of nor-
mal (Figs. 5D and 6B). Although the waveform and
timing of the response of subject V:2 suggest that this
b-wave was mainly driven by cone bipolars, and thatFig. 4. Functional Wndings associated with mutations at codon 135 (class A phenotype). (A and B) Examples of visual Welds of children harboring the
R135L and R135W mutations, respectively. By late teenage years, severe concentric visual Weld constriction is already present. (C and D) Mixed dark-
adapted ERG responses recorded in subjects with these mutations. All responses are severely diminished (normal amplitude scale for these responses: 80
V/division). (E) The plot of normalized amplitude of mixed DA ERG b-wave (expressed as percent of the lowest limit of normal) vs. age for patients with
these mutations. The mixed ERGs of patients harboring the R135L mutation remain signiWcantly better preserved than those with the R135W mutation.
The overall kinetics of ERG decay deduced from this cross-sectional data appear comparable for the two mutations. However, longitudinal measurements
from the R135L proband and two children harboring the R135W mutations (shown encircled) suggest diVerent progression rates vs. baseline between the
two mutations: a 25% loss vs. baseline (age 3) was seen over a 7-year period for the R135L proband (on average, 3.5% per year), whereas a 50% loss 1 year
from baseline was observed for the two R135W children.
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reXected rod bipolar activation (see below), this Wnding
provides evidence for abnormal and reduced yet persis-
tent and measurable rod-driven activity in children
aVected by the G188R mutation.
In subsequent decades, a progressive age-dependent
decline of mixed ERG b-wave amplitudes was seen
(Fig. 6B). By age 60, the visual Weld was severely constricted
(Fig. 6A), the mixed ERG of G188R patients was still
recordable although reduced to 2% of normal (Fig. 5D),
and good visual acuity was still preserved, in line with the
observed preservation of macular integrity documented
ophthalmoscopically (see Supplementary Table 3 for fur-
ther details). The integrity of foveal cones is therefore main-
tained until late in the course of this form of ADRP. In
summary, these features characterize the phenotype associatedwith the G188R mutation as a class B2 mutant (Cideciyan
et al., 1998).
Fig. 5D also shows that subjects harboring the G188R
mutation have signiWcantly smaller responses than the sub-
ject with the P180A mutation. In addition, the estimated
yearly ERG loss progression rate seen in two patients with
the G188R mutation was signiWcantly higher (on average,
21.5%) than the 8% observed with the P180A mutation.
This correlates well with the regional nature of disease in
the latter case. Of relevance to the in vitro and computa-
tional data presented later, the observed G188R yearly
average rate of disease progression was less than half that
of R135W younger patients, but signiWcantly greater than
the R135L child followed serially. Hence, in addition to the
greater severity from onset of disease associated to codon
135 mutations, this observation also suggests potential forFig. 5. Functional Wndings associated with the P180A RHO mutation. (A) Goldmann visual Welds demonstrating modest loss of the superior Weld and rel-
ative scotomas in the superior hemiWeld, consistent with the altitudinal disease observed ophthalmoscopically. The regional predilection of the disease for
the inferior retina is conWrmed by the monochromatic automated perimetry plots shown in (B). These plots also show some loci exhibiting rod sensitivity
losses (RSL) also in the inferior hemiWeld at loci where no cone sensitivity loss (CSL) is seen, a phenomenon that is typical of class B1 phenotypes. (C)
Representative pairs of ISCEV-standard ERG responses (black traces: baseline; blue traces: 16 months later). The Xash intensities in cd s/m2 are given to
the left of each response. DA D dark-adapted; LA D light-adapted. A response at ¡0.31 cd s/m2 at which the b-wave splitting (arrow) discussed further in
the text and in Appendix A is also shown. (D) The plot of normalized amplitude of mixed DA ERG b-wave (expressed as percent of the lowest limit of
normal) vs. age for patients with RHO mutations P180A and G188R. The mixed ERG of the proband with the P180A mutation is signiWcantly better pre-
served than that of patients with the G188R mutation, whose response decline is Wt well by an exponential function. The observed average yearly rate of
ERG decline deduced from longitudinal observations (encircled data points) was 21.5% for the G188R mutation and 8% for the P180A.
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patients harboring the G188R mutation compared to those
with R135W.
3.2.3. Electroretinographic evidence for anomalous 
rod-driven responses in patients with class B phenotypes
Subject IV:4 from the P180A pedigree also showed a dis-
tinctive splitting of the DA b-wave at ¡0.31 cd s/m2 stimuli,
which is approximately 0.5 log units below the ISCEV stan-
dard Xash range (Fig. 5C, arrow). The second, delayed b-
wave peak (75 ms) was shown to be genuinely rod-driven
by its disappearance when these responses were re-recorded
immediately following the LA series and by its progressive
re-appearance as DA responses were allowed to recover
(illustrated in the Supplementary Wgure). A similar phe-
nomenon was documented also for the asymptomatic child
(subject V:2) harboring the G188R mutation in response to
a standard mixed Xash of 0.18 cd s/m2 (also illustrated in the
Supplementary Wgure).
It appears reasonable to conclude that this distinctive
DA ERG b-wave splitting was consistent with the activity
of rod-driven bipolar cells from areas of greater rod disease
severity, responding more slowly than the bipolar cells from
areas of well preserved rod- (and cone-) mediated activity.
Furthermore, not only was the Wrst—and normal in tim-
ing—peak diminished at follow up in the P180A proband,
but the second delayed b-wave peak was also markedly
attenuated at follow-up testing (not shown). This Wnding is
suggestive of greater disease progression for rods with
initially more severe disease.3.3. Computational studies
The crystal structure of rhodopsin is known (Palczewski
et al., 2000) and can thus be used to infer likely eVects of
amino acid substitutions on stability based on the local
environment of each residue provided by the structure. Two
measures of stability were investigated, misfolding and the
decay rate of the light-activated, Metarhodopsin II state.
Three diVerent algorithms were compared, I-Mutant2.0
(Capriotti et al., 2005), DFIRE (Zhou & Zhou, 2002), and
FOLDX (Guerois et al., 2002).
The results of these computations are shown in detail in
Supplementary Table 5. The overall accuracies of all three
methods were relatively low. This indicates that the local
structure surrounding the mutation site alone is not suYcient
to account for the experimentally observed eVects on rho-
dopsin stability and folding. Usually, this is interpreted as
long-range eVects by the mutations, altering the folding or
conformation of the protein. To investigate such long-range
eVects, we utilized the previously applied FIRST analysis
method (Rader et al., 2004). In this analysis, we found that
the core of stability includes several clusters, the largest of
which is located surrounding the conserved disulWde bond
between residues Cys110 and Cys187 lining the retinal binding
pocket. The residues of the largest cluster are circled in red in
Fig. 1. The two mutations in the second intradiscal loop,
Gly188 and Pro180, are both part of this cluster. It was previ-
ously shown that >90% of the residues in this cluster show
misfolding upon mutation, indicating a role of this cluster in
the folding of rhodopsin (Rader et al., 2004). Thus, it isFig. 6. Functional Wndings associated with the G188R RHO mutation. (A) Examples of visual Welds in a 42- and a 64-year-old subject. Despite the marked
constriction eventually ensuing in these patients, subject III:7 retained 20/20 vision in the left eye (shown here). (B) Examples of mixed ERG responses
from this family, showing the far better preservation of the responses compared to codon 135 mutations, but the greater disease severity compared to the
P180A mutation. The response of case V:2 also displays a b-wave splitting reminiscent of that seen in the P180A proband, and shown to have the same ori-
gin (i.e., rod-driven) in the Supplementary Wgure.
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in misfolding of rhodopsin. The FIRST simulated unfolding
also predicted several other, smaller regions of structural sta-
bility. The largest of these is a cluster of residues at the cyto-
plasmic end of helix 3 and the second cytoplasmic loop,
highlighted by blue circles in Fig. 1. Arg135 is part of this
cluster, strongly suggesting a role of this residue in structural
stability of rhodopsin. Mutation at this site would therefore
be expected to cause misfolding.
3.4. Stability, misfolding, aggregation, and glycosylation of 
rhodopsin mutants
Expression of the four RHO mutations presented herein
by transient transfection in COS-1 cells, reconstitution with
11-cis retinal and puriWcation on 1D4-antibody aYnity
chromatography showed that the yield of fully folded,
chromophore-containing rhodopsin was low in all four
mutants indicating a tendency to misfold in all four cases.
Representative absorption spectra of the four mutants and
the WT are shown in Fig. 7A. Spectra are normalized to the
absorbance at 280 nm (opsin). The ratios between the
absorbance at 500 nm as compared to that at 280 nm, a
direct measure of the ratio between folded, retinal-boundprotein and misfolded protein are summarized in Table 1.
In relative terms to one another, the degree of misfolding
varied considerably. The P180A and the R135L mutations
caused the least misfolding, whereas G188R and R135W
were both severely misfolded. The Wnding that all four
mutants cause misfolding is in very good agreement with
the predictions by the FIRST method.
Next, we investigated if the folded portions of the
mutants diVered in stability. Fig. 7B shows the decrease in
500 nm chromophore at 55 °C, an indicator of thermal sta-
bility of rhodopsin. WT rhodopsin shows a 10% decrease
Table 1
Degrees of misfolding of rhodopsin mutants as compared to wild type
a A280, opsin absorbance; A500, absorbance after retinal binding. Since
misfolded rhodopsin does not give rise to 500 nm absorbance peaks,
higher ratios are indicative of greater misfolding. Values are the averages
obtained for six elution fractions.
A280:A500 absorbance ratio
a (means § SD)
Wild type 2.0 § 0.2
R135L 5.6 § 0.3
R135W 10.2 § 1.8
P180A 5.9 § 0.7
G188R 12.7 § 3.0Fig. 7. In vitro misfolding, stability, glycosylation, and aggregation state of rhodopsin mutants as compared to wild type. (A) Representative absorbance
rhodopsin spectra normalized to the 280 nm absorbance: wild type (black), R135L (teal green), R135W (light green), P180A (red), and G188R (blue). (B)
Rhodopsin stability measured by loss of 500 nm chromophore over time at 55 °C. Absorbance spectra were measured in time intervals and the decrease in
absorbance at 500 nm was expressed as percent of intact structure. (C) Western-blot of wild type (WT) and rhodopsin mutants (R135L, R135W, P180A,
and G188R) expressed transiently in COS-1 cells. Protein concentrations were adjusted according to expression level and approximately 0.075 g was
loaded. For each mutant or the wild type, equivalent amounts were analyzed before (¡) and after (+) treatment with PNGase F.
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ilar but lower stability than wild type, while P180A was
highly unstable: within 60 min, greater than 95% of the
original chromophore was lost. These results are in good
agreement with the stability predictions. We predicted an
increase/no change in stability for both R135 mutants, and
experimentally observed a behavior similar to wild type
rhodopsin, whereas we predicted a highly destabilizing
eVect of the P180A mutation, which is what we observed in
the experiment. We could not carry out measurements for
G188R due to the low expression yields of this mutant.
Finally, we compared the SDS–PAGE mobility of the
four RHO mutants with the wild type. A Western-blot
using the 1D4-antirhodopsin monoclonal antibody is
shown in Fig. 7C. First, all four mutants display a markedly
diVerent appearance. Normal appearance is a “smear” of a
broad band corresponding to heterogeneous glycosylation
and monomeric aggregation state, as shown in Fig. 7C in
the WT control. The R135L and P180A mutants exhibited
a behavior the most similar to wild type, but with increased
dimeric and tetrameric conWgurations. In addition, P180A
showed degradation products and lesser glycosylation than
the wild type and the R135L mutant. Unlike these mutants,
R135W and G188R were very diVerent from the wild type.
R135W and G188R displayed defects in glycosylation and
for R135W much of the protein was aggregated (tetrameric
band at 100 kDa). G188R displayed mobility consistent
with a strong tendency to dimerize.
4. Discussion
We have reported the manifestations and the variability
in severity and disease progression rates of ADRP associ-
ated with RHO sequence changes involving diVerent por-
tions of the rhodopsin molecule (the cytoplasmic edge of
H3: R135W and R135L; and the second intradiscal loop:
P180A and G188R). We characterized the phenotype of
several new families and appraised the phenotype of the
two previously reported Italian families within the classiW-
cation system of Cideciyan et al. (1998). The G188R muta-
tion is thus added to the list of those classiWed according to
this system, supplementing the previously published data
(Del Porto et al., 1993) with additional longitudinal obser-
vations. Lastly, the availability of data starting from the
pediatric age range allowed us to perform a direct compari-
son since the early stages of disease expression between the
R135W (Pannarale et al., 1996) and the R135L mutations.
We directly compared the eVects of the four amino acid
substitutions on the folding, stability, and glycosylation
patterns of rhodopsin by computational predictions and
in vitro studies of the rhodopsin mutants.
All residues involved in these four families (Arg135,
Pro180, and Gly188) are highly conserved residues in rhodop-
sins across all species. The four mutations reported here
varied with respect to the types of amino acid substitutions.
The mutations at codon 135 both lead to a change in size
and charge for this residue. The large and basic R aminoacid is replaced by a smaller non-polar one in the R135L
mutant, and by a non-polar, large and aromatic one in the
R135W mutant. The P180A substitution replaces medium
size hydrophobic residue (P) with a hydrophobic but
smaller (A). Unlike these mutations, G188R leads to the
substitution of a small, non-polar amino acid (G) to a large
and basic one (R). These diVerences create the premises for
diVerent structural and, potentially, phenotypic eVects.
4.1. Computational and in vitro analyses correlate with 
greater disease severity associated with the R135W mutation
The most severe disease (class A) was associated with the
mutations at codon 135. This Wnding is consistent with pre-
vious independent reports of ADRP associated with muta-
tions aVecting the Arg135 residue (Jacobson, Kemp, Sung, &
Nathans, 1991; Jacobson, Kemp, Cideciyan, & Nathans,
1996; Ponjavic, Abrahamson, Andreasson, Ehinger, & Fex,
1997). We could successfully document the persistence of
recordable ERG responses in children from both the
R135W and the R135L family. This data show that ERGs
are signiWcantly larger and better preserved over time in
subjects with the R135L mutation.
The consistently severe disease associated with these two
mutations underscores the functional importance of this
residue. The Glu134 and Arg135 residues are part of the
highly conserved D/E R Y motif at the edge of H3 in the
rhodopsin 3D structure (Li, Edwards, Burghammer, Villa,
& Schertler, 2004; Palczewski et al., 2000) (see Fig. 1), an
important interaction site with transducin. In vitro studies
of bovine rhodopsin mutants have shown that both R135L
and R135W bound retinal almost in a wild type-like fash-
ion under the conditions used for reconstitution and puriW-
cation, but were unable to activate the G protein (Shi et al.,
1998). Prior studies of human rhodopsin had led to the clas-
siWcation of both R135L and R135W as class IIb mutants
(Sung et al., 1993), i.e., defective in their ability to bind
11-cis retinal, folding, and stability, and partial transporta-
tion to cell surface. By the criteria used in previous studies,
these two mutants did not diVer in their properties. Our
computational and in vitro studies support the conclusion
that the folding in both of the mutants is severely impaired
and show that the predicted misfolding of the R135W
mutant is signiWcantly greater than the R135L and that its
glycosylation state is the most defective of all four mutants
studied. These Wndings provide, at least in part, a potential
explanation at the molecular level for the greater disease
severity caused by the R135W amino acid substitution.
4.2. P180A: Evidence for pathogenicity of this amino acid 
substitution and rationale for the observed mild disease 
phenotype
Unlike the above mutations, the two changes aVecting
the second intradiscal loop were associated with signiW-
cantly milder phenotypes. The P180A substitution led to
the least severe of the manifestations, with evidence for
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history of high environmental light exposure, and a seem-
ingly mild class B2 phenotype in his mother who did not
share this environmental exposure. The potential for class
B2 manifestations in association with the P180A mutation
appears similar to what has been reported for the P23H-
associated phenotype (Cideciyan et al., 1998). In consider-
ation of the recent evidence that dogs harboring the T4R
RHO mutation are exquisitely sensitive to light damage
(Cideciyan et al., 2005; Zhu et al., 2004), the predilection for
inferior retinal disease in the proband may reXect a similar
predisposition in humans, as already suggested by clinical
(Heckenlively, Rodriguez, & Daiger, 1991) and rat (Organ-
isciak, Darrow, Barsalou, Kutty, & Wiggert, 2003; Walsh,
van Driel, Lee, & Stone, 2004) data for the P23H mutation.
Like in Sohocki et al. (2001), the P180A change observed
in our proband could not be conWrmed by segregation stud-
ies in other family members. However, the Pro180 residue is
highly conserved, and it is in the proximity of Glu181, a resi-
due that has been reported to cause ADRP likely to result
in class A disease (Cideciyan et al., 1998). Also, in vitro rho-
dopsin deletion studies have shown that removal of the
Pro180 residue yields a structurally and functionally defec-
tive rhodopsin molecule (Doi, Molday, & Khorana, 1990).
Therefore, the introduction of a smaller amino acid,
alanine, in place of the wild type proline likely induces a
destabilization of the aforementioned network. The
pathogenicity of the P180A mutation was strongly corrob-
orated by the computational and in vitro evidence herein
provided.
4.3. G188R mutation: A rationale for intermediate disease 
severity
The G188R mutation was associated only with class B2
features, without regional predilection. Our data show that
cone function is at least partially maintained for life in
patients with this mutation and that there may be room for
early rod-speciWc interventions. The in vitro behavior of the
G188R mutant has been studied before (Liu, Garriga, &
Khorana, 1996; Sung et al., 1991), conWrming our predic-
tion that this mutant is misfolded (Del Porto et al., 1993).
The mutation at codon 188 introduces a large and basic
arginine residue that is likely to preclude the correct folding
of the intradiscal portion of the molecule mediated by the
formation of a disulWde bond between Cys187 and Cys110
(Davidson, Loewen, & Khorana, 1994; Hwa et al., 1999;
Karnik, Sakmar, Chen, & Khorana, 1988). Like Pro180, also
Gly188 is part of the folding core predicted by the FIRST
method. The in vitro experimental data presented herein
show that the G188R mutation causes much more pro-
nounced misfolding than that observed for the P180A
mutation.
Although other diVerences are likely to exist in the
in vitro behavior of these two mutants, the lesser degree of
misfolding of the P180A mutant compared to the G188R
correlates well with the milder phenotype associated withthe former amino acid change. However, the G188R
mutant was as severely misfolded as the R135W, which
caused the most severe disease of all in our series. Longitu-
dinal measurements also suggest that the rate of disease
progression is about twice as fast in patients with the
R135W mutation compared to patients harboring the
G188R one. Likewise, the P180A and the R135L mutations
were comparable in severity of misfolding, but the latter
resulted in a much more severe phenotype. Therefore,
misfolding alone is an insuYcient criterion to account for
phenotypic diVerences among these four mutants.
One plausible explanation is the known lack of trans-
ducin activation by the Arg135 mutants (Shi et al., 1998).
Thus, in the Arg135 mutations, misfolding and impairment
in signalling function may be acting together to cause a
stronger phenotype than the G188R and P180A mutations.
It will be an important goal of future studies to characterize
the interactions of the G188R and P180A mutants with
transducin, arrestin, and rhodopsin kinase, and contrast
their properties between themselves and with those of the
two Arg135 mutants. It would also appear important to
study these behaviors in the simultaneous presence of WT
rhodopsin, since in humans aVected by disease the potential
for expression of the WT allele remains, and the extent to
which this occurs may be directly correlated to the behavior
of the mutant allele. This is a particularly exciting avenue
for further research because evidence is mounting that
rhodopsin in the ROS is in a dimeric state (reviewed in
Palczewski, 2006) and we found preliminary evidence that
G188R may have an increased dimer aYnity, providing a
possible additional explanation for the less severe pheno-
type associated with this mutant despite misfolding compa-
rable to R135W.
5. Conclusions
In summary, we have shown that phenotypic diVerences
exist between mutations aVecting the same portion of the
molecule. These diVerences pertain to disease severity and
progression rates, and in part also to phenotypic classes. A
combination of computational folding predictions and
in vitro assays allowed us to provide potential explanations
for the clinical disease gradient observed for these four
mutations (speciWcally, P180A>G188R>R135L>R135W).
Caution must always be exerted, however, in drawing
in vivo human conclusions from in vitro and animal data.
For example, previous in vitro studies could not provide
evidence for mislocalization of another mutation present-
ing with a mixed class B1 and B2 phenotype, P23H. Rho-
dopsin mutated at this codon mislocalizes to the synaptic
terminal of photoreceptors in mice with a human P23H
rhodopsin transgene (Roof, Adamian, & Hayes, 1994) but
not in mice expressing a murine transgene (Wu et al., 1998)
or in Drosophila (Galy, Roux, Sahel, Leveillard, &
Giangrande, 2005). The role of this aberrant localization in
disease pathogenesis and progression of this and other
forms of RHO-linked ADRP is not well understood.
4566 A. Iannaccone et al. / Vision Research 46 (2006) 4556–4567Recent evidence for a direct and light-independent degener-
ative eVect of mislocalized rhodopsin has been provided in
Xenopus laevis retinas harboring a C-terminus mutant
equivalent to the Q344X human counterpart (Tam, Xie,
Oprian, & Moritz, 2006). Recent in vitro data also suggest
that the P23H mutant may result in formation of aggre-
somes and generalized impairment of the ubiquitin protea-
some system (Illing, Rajan, Bence, & Kopito, 2002; Saliba,
Munro, Luthert, & Cheetham, 2002). Therefore, the in vivo
intracellular fate of mutant rhodopsin molecules may also
be a very important variable to characterize to fully appre-
ciate the consequences and mechanism(s) of disease linked
to RHO mutations.
IdentiWcation and characterization of RHO mutations
remains important because it continues to improve our
understanding of RP pathophysiology and yields clinically
important prognostic information. The combined use of
clinical and functional data with computational and
in vitro expression experiments show promise as an
approach to improve further the understanding of RP
caused by RHO mutations and test hypotheses that each
approach, when used alone, cannot address eVectively.
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